MEIPのチャート
MEIPの企業情報
| symbol | MEIP |
|---|---|
| 会社名 | MEI Pharma Inc （MEIファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 MEIファーマ(MEI Pharma Inc.)(旧名:Marshall Edwards Inc)はがんの治療向けの薬物と治療の臨床開発に焦点を当てる癌治療に従事する会社である。同社の臨床薬候補のポートフォリオには、Pracinostat、ME-344及びME-401が含まれる。Pracinostatは、経口で利用可能なヒストンデアセチラーゼ（HDAC）阻害剤であり、急性骨髄性白血病（AML）と骨髄異形成症候群（MDS）などの血液疾患の治療に適応する。ME-344は、イソフラボン系ミトコンドリア阻害剤であり、急速に増殖する細胞中の末端呼吸鎖複合体のミトコンドリア成分を標的とする。ME-401は、血液癌細胞の増殖と生存に重要な役割を果たす分子標的であるホスファチジルイノシトイド3-キナーゼ（PI3K）デルタの経口阻害剤である。Pracinostatは、進行性血液悪性腫瘍と固形腫瘍適応症における複数の第I相と第II相臨床試験で試験される。 MEIファ―マは米国の腫瘍専門の医薬品メ―カ―。がん治療のための新薬の臨床開発に従事。主力製品候補の「Pracinostat」は、骨髄異形成症候群や急性骨髄性白血病などの進行性の血液疾患のために開発されている、経口投与可能なヒストンデアセチラ―ゼ阻害剤である。本社はサンディエゴ。 mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com. |
| 本社所在地 | 3611 Valley Centre Drive Suite 500 San Diego CA 92130 USA |
| 代表者氏名 | Christine Anna White クリスティーナ・アンナ・ホワイト |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-792-6300 |
| 設立年月日 | 36861 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.meipharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/meip |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.53300 |
| 終値（lastsale） | 3.75 |
| 時価総額（marketcap） | 266574015 |
| 時価総額 | 時価総額（百万ドル） 266.68290 |
| 売上高 | 売上高（百万ドル） 1.62200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 163.93990 |
| 当期純利益 | 当期純利益（百万ドル） -40.06800 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 MEI Pharma Inc revenues decreased 93% to $1.6M. Net loss totaled $40.1M vs. income of $2.7M. Revenues reflect License revenue decrease from $20.9M to $0K Research and development revenue decrease of 32% to $1.6M. Net loss reflects Research and development - Balancing val increase from $6.4M to $15.9M (expense) General and administrative - Balancing v increase of 8% to $7.7M (expense). |
MEIPのテクニカル分析
MEIPのニュース
MEI Pharma Promotes COO David Urso To Succeed Daniel Gold As President And CEO 2023/06/02 13:08:38 EIN News Pharmaceuticals
Pharmaceutical company MEI Pharma , Inc. (MEIP) announced Friday that, … in 2010. Urso joined MEI Pharma in April 2014 with nearly … and general counsel at Tioga Pharmaceuticals , a privately held drug development …
MEI Pharma CEO Daniel Gold Stepping Down 2023/06/02 12:29:16 EIN News Pharmaceuticals
… successor. Urso joined MEI Pharma in 2014 and has been … board. On Thursday, MEI Pharma said its board of directors … apiece, significantly undervalued the pharmaceutical company and is less appealing … than a bid from Infinity Pharmaceuticals . Write to Chris Wack …
MEI Pharma CEO Daniel Gold to depart, David Urso to succeed 2023/06/02 12:16:23 Seeking Alpha
MEI Pharma (MEIP) has announced that Daniel P. Gold, Ph.D’s tenure as the President and CEO of MEI will end on June 2, 2023 and the Co.’s board of directors has appointed David M
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor 2023/06/02 12:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company’s previously announced succession plan, Daniel P. Gold, Ph.D’s tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company’s board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has bee
Spurned MEI Pharma private suitors call rejection ''derogation of fiduciary duties'' 2023/06/01 20:50:12 Seeking Alpha
Two private equity firms whose bid for MEI Pharma was rejected by the company board called the rejection a complete derogation of its fiduciary duties. Read more here.
MEI Pharma GAAP EPS of $0.08 beats by $0.29, revenue of $32.74M beats by $29.4M (NASDAQ:MEIP) 2023/02/09 21:52:08 Seeking Alpha
MEI Pharma press release (NASDAQ:MEIP): Q2 GAAP EPS of $0.08 beats by $0.29.Revenue of $32.74M (+79.7% Y/Y) beats by $29.4M.
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights 2023/02/09 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2022, and highlighted recent corporate events. “MEI anticipates reporting key clinical data readouts on two clinical-stage oncology candidates, voruciclib and ME-344, around the end of the calendar year for each program,” said Daniel P. Gold, Ph.D., president and chief executive officer of ME
Our Attention Has Been Attracted to MEI Pharma Inc. (NASDAQ:MEIP) 2023/02/08 17:24:00 US Post News
MEI Pharma Inc. (MEIP)’s stock has witnessed a price declined of -8.45% from the previous close with its current price standing at $0.32. Its current price is -85.61% under its 52-week high of $2.20 and 54.40% more than its 52-week low of $0.21. Based on the past 30-day period, the stock price is -5.57% below […]
Will MEI Pharma Inc. (NASDAQ: MEIP) Stock Boom Or Bust From Here? 2023/01/21 15:30:00 Marketing Sentinel
During the last session, MEI Pharma Inc. (NASDAQ:MEIP)’s traded shares were 0.4 million, with the beta value of the company hitting 0.93. The 52-week high for the MEIP share is $2.37, that puts it down -597.06 from that peak though still a striking 38.24% gain since the share price plummeted to a 52-week low of … Will MEI Pharma Inc. (NASDAQ: MEIP) Stock Boom Or Bust From Here? Read More »
Investing in MEI Pharma Inc. (MEIP) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/18 14:08:00 US Post News
In Tuesday’s session, MEI Pharma Inc. (NASDAQ:MEIP) marked $0.34 per share, up from $0.33 in the previous session. While MEI Pharma Inc. has overperformed by 2.63%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MEIP fell by -86.16%, with highs and lows ranging from $2.50 to […]
MEI Pharma stock trades higher as FY22 revenue grows 17% 2022/09/09 14:58:10 Seeking Alpha
MEI Pharma (MEIP) stock rose ~3% on Sept. 9 after FY22 revenue increased ~17% Y/Y.For the fiscal year ended June 30 2022, revenue amounted to ~$40.9M, compared to ~$34.8M in 2021.Net…
MEI Pharma GAAP EPS of -$0.50 misses by $0.03, revenue of $40.7M misses by $1.09M (NASDAQ:MEIP) 2022/09/08 20:15:02 Seeking Alpha
MEI Pharma press release (MEIP): FY GAAP EPS of -$0.50 misses by $0.03.Revenue of $40.7M (+17.0% Y/Y) misses by $1.09M.The adjusted net loss was $75.2 million, compared to an…
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights 2022/09/08 20:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2022. "This past fiscal year was marked by progress on multiple fronts, including the first patient dosed in our Phase 3 COASTAL study, strong zandelisib data reported from the global Phase 2 TIDAL study, reporting of data from our voruciclib and ME-344 programs, and key appointments to our execu
MEI Pharma FY 2022 Earnings Preview 2022/09/07 19:08:48 Seeking Alpha
MEI Pharma (MEIP) is scheduled to announce FY earnings results on Thursday, September 8th, after market close.The consensus EPS Estimate is -$0.51 and the consensus Revenue Estimate is…
Earnings Outlook For MEI Pharma 2022/09/07 15:13:02 Benzinga
MEI Pharma (NASDAQ: MEIP ) is set to give its latest quarterly earnings report on Thursday, 2022-09-08. Here''s what investors need to know before the announcement. Analysts estimate that MEI Pharma will report an earnings per share (EPS) of $-0.19. MEI Pharma bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com